Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- MBRX -10.3%, XGTI -0.6%, INSY -0.6%
Select EU financial related names showing weakness:
- DB -1.6%, PUK -1.6%, BBVA -1.4%, CS -0.7%, BCS -0.7%
Other news:
- EKSO -10.2% (entered into definitive agreements with certain institutional investors providing for the purchase and sale of 3,732,356 shares of common stock at a price of $3.14/share)
- UTHR -9.1% (announces that regulatory delays will result in postponement of the planned U.S. launch of the RemoSynch Implantable System for Remodulin until 2018 ), MBOT -2.4% (files for $75 mln mixed securities shelf offering)
- NTRP -1.9% (files for $100 mln mixed securities shelf offering)
- MYL -1.3% (Mylan N.V. provides update on Meridian Medical Technologies', a Pfizer (PFE) Company, expanded voluntary worldwide recall of EpiPen auto-injecto)
Analyst comments:
- ACOR -5% (downgraded to Neutral from Overweight at JP Morgan; also downgraded to Neutral from Buy at Janney)
- ACN -2.3% (downgraded to Sell from Neutral at Goldman)
- IBKR -2% (downgraded to Underperform from Market Perform at Wells Fargo